Cargando…

Treatment for hyperuricemia and gout in Japan: Aspect of prescription and duration

Detalles Bibliográficos
Autor principal:	Zhang, Di
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Hyperuricemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380139/ https://www.ncbi.nlm.nih.gov/pubmed/35818832 http://dx.doi.org/10.1111/jch.14538

Ejemplares similares

The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data
por: Akari, Seigo, et al.
Publicado: (2022)

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
por: Kario, Kazuomi, et al.
Publicado: (2021)

Gout. Novel therapies for treatment of gout and hyperuricemia
por: Terkeltaub, Robert
Publicado: (2009)

Susceptibility genes of hyperuricemia and gout
por: Nian, Yue-Li, et al.
Publicado: (2022)

A concise history of gout and hyperuricemia and their treatment
por: Nuki, George, et al.
Publicado: (2006)

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
por: Pérez-Ruiz, Fernando, et al.
Publicado: (2019)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean
por: Ahn, Joong Kyong
Publicado: (2023)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

An update on the genetic architecture of hyperuricemia and gout
por: Merriman, Tony R
Publicado: (2015)

Pharmacological effects of Chatuphalatika in hyperuricemia of gout
por: Sato, Vilasinee Hirunpanich, et al.
Publicado: (2018)

The role of the Mediterranean diet in hyperuricemia and gout
por: Stamostergiou, Julie, et al.
Publicado: (2018)

Why Does Hyperuricemia Not Necessarily Induce Gout?
por: Zhang, Wei-Zheng
Publicado: (2021)

Rhazes' Prescriptions in Treatment of Gout
por: Changizi Ashtiyani, S, et al.
Publicado: (2012)

Atypical musculoskeletal manifestations of gout in hyperuricemia patients
por: Sakti, Muhammad, et al.
Publicado: (2019)

Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia
por: Cao, Ling, et al.
Publicado: (2021)

The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics
por: Wu, Xinghong, et al.
Publicado: (2023)

Associations of metal exposure with hyperuricemia and gout in general adults
por: Xu, Jing, et al.
Publicado: (2022)

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
por: Janssen, C. A., et al.
Publicado: (2018)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Circulating microRNA alternations in primary hyperuricemia and gout
por: Bohatá, Jana, et al.
Publicado: (2021)

N-Butyrylated hyaluronic acid ameliorates gout and hyperuricemia in animal models
por: Li, Lanzhou, et al.
Publicado: (2019)

The Interaction Between Dietary Fructose and Gut Microbiota in Hyperuricemia and Gout
por: Fang, Xin-yu, et al.
Publicado: (2022)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Potential Molecular Mechanisms of Plantain in the Treatment of Gout and Hyperuricemia Based on Network Pharmacology
por: Liu, Pei, et al.
Publicado: (2020)

Exploring RNA modifications, editing, and splicing changes in hyperuricemia and gout
por: Huang, Chung-Ming, et al.
Publicado: (2022)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Gout, not hyperuricemia alone, impairs left ventricular diastolic function
por: Lin, Jing-Chi, et al.
Publicado: (2015)

The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout—An Update
por: Eckenstaler, Robert, et al.
Publicado: (2021)

Hidden gout- Ultrasound findings in patients with musculo-skeletal problems and hyperuricemia
por: Reuss-Borst, Monika A, et al.
Publicado: (2014)

Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout
por: Krishnan, E., et al.
Publicado: (2013)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements
por: Li, Qianrui, et al.
Publicado: (2019)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

Study of epidemiological aspects of hyperuricemia in Poland
por: Kostka-Jeziorny, Katarzyna, et al.
Publicado: (2019)

Potential molecular mechanisms of Ermiao san in the treatment of hyperuricemia and gout based on network pharmacology with molecular docking
por: Geng, Yin-Hong, et al.
Publicado: (2022)

Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout
por: Wang, Zhilei, et al.
Publicado: (2022)

Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q8t4gs8gottc3oh6ovqvk1ffo4